Israeli drug development company Protalix Biotherapeutics Inc. (NYSE:The latest results was positive 12-month on-treatment data from the first 16 out of the 22 adult patients enrolled in its BRIDGE Phase III study. Protalix VP medical affairs Dr. Raul Chertkoff said, "The results suggest the strong potential benefit of pegunigalsidase alfa on renal function for Fabry patients." RELATED ARTICLES Protalix reports positive results in Fabry comparative drug trial FDA fast tracks Protalix's Fabry disease drug Protalix cuts 20% of workforce in Karmiel Protalix Biotherapeutics signs deal worth up to $370m The 12-month interim data from the first 16 of 22 adult patients enrolled (9 males and 7 females) demonstrate a mean improvement in kidney function, in both male and female patients, when switched from agalsidase alfa to pegunigalsidase alfa. Published by Globes, Israel business news - en.globes.co.il - on October 18, 2019 © Copyright of Globes Publisher Itonut (1983) Ltd. 2019
